AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 11 min read$ORKA

Sandler Laura Lee sold $459K of ORKA

Sandler Laura Lee (Chief Operating Officer) sold 5,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $91.82 ($91.05–$92.01, $0.46M total) across 2 trades on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sandler Laura Lee
Published Sep 1, 2026, 10:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 11:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ORKA
Neutral
high confidence
Mentioned
$ORKA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ORKANeutralLow
01

Why it matters

The sale represents a modest reduction in insider stake with limited market impact.

02

Market read

Routine insider sale; unlikely to move the stock significantly.

03

What to watch

Potential upcoming catalyst not disclosed; sale may be unrelated.

Relevance 3/10Novelty 2/10Timing: 2026‑09‑01 filing

Background

Form 4 filing discloses insider transactions; investors monitor for material changes.

Company-level read

Ticker impact

$ORKANeutralHigh confidence
Context

Chief Operating Officer sold 5,000 shares for $459K via a 10b5‑1 plan.

Expected impact

Minimal effect on stock price.

Evidence & confidence

Sale size is small relative to float and disclosed via Form 4, typical for insiders.

Market effects

Sector

No broader sector impact; biotech insider sales are routine.

Regional

None

Global

None

Counterpoint

What could challenge this read

If the insider is cashing out due to concerns, could signal downside.

Key entities

  • Company
    Oruka Therapeutics, Inc.

    Biotech firm listed on NASDAQ under ORKA.

  • Insider
    Laura Lee Sandler

    Chief Operating Officer of Oruka Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ORKA insider trading history →

Related articles

OCT 27
$ORKAHighAI 8/10

H.C. Wainwright reiterates Oruka Therapeutics stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $120 price target for Oruka Therapeutics (ORKA) after positive Phase 2b trial results for ORKA-001 in psoriasis. The stock rose 14% last week to $90.33, up 226% over a year. Analysts' price targets range from $117 to $200. The trial showed 61% of high-dose patients achieved PASI 100 at Week 16. Phase 3 trials are planned for 2027.

investing.com2 min
OCT 27
$ORKAMedAI 8/10

Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study

Oruka Therapeutics reported that its drug ORKA-001 achieved 61% complete skin clearance in a Phase IIb psoriasis study. The company plans to advance the 600-milligram dose into Phase III in early 2027, pending regulatory discussions. Oruka also expects to report week 52 data from the EVERLAST-A study in December, which will test the drug's potential for annual maintenance dosing. The company has over $1 billion in cash, providing runway through a potential biologics license application filing.

finance.yahoo.com2 min